About the IOV-IL2-101 trial
Patients with previously treated, unresectable, or metastatic melanoma will receive IOV-3001 either before or after lifileucel.
The trial will evaluate whether IOV-3001 is safe and determine the best dose. Additionally, it will determine the potential of IOV-3001 to:
- Produce antibodies
- Reduce tumor size
- Reduce tumor growth
- Extend patients’ lives without their cancer worsening
Patients may be eligible to participate in this trial if they:
- Are 18 years or older
- Have unresectable or metastatic melanoma
- Have previously received treatment for melanoma
Here is what patients can expect in the trial
If patients qualify, they will be enrolled in Phase 1 of the trial and will:
- Part 1: Receive IOV-3001 before lifileucel treatment
- Part 2: Receive IOV-3001 after lifileucel, instead of aldesleukin
Parts 1 and 2 will also determine the recommended dose for Phase 2 of the trial, in which IOV-3001 is assessed for effectiveness as it moves through the body.
Find a trial location
The current trial site is in Nashville, Tennessee.
Get started
This website is intended for a U.S. audience. TIL cell therapy is not yet approved by any regulatory or health agency for the investigational uses described in this website. This website is for educational purposes only and is not intended to replace discussions with a healthcare professional.
